Group 1 - Company Jiutian Pharmaceutical plans to invest no more than 400 million yuan to acquire the patent and technology for the small molecule analgesic drug YJ2301 from Suzhou Yuanju [1] - The last trading day for Jian Gong Convertible Bond is set for December 16, 2025 [1] - The proportion of convertible bonds held by Youmeili Investment Management in Wanfu Convertible Bond has reached 20%, with a total of 1,230,467 bonds held as of December 11, 2025, accounting for 20.51% of the total issuance [1] Group 2 - Shengxun Convertible Bond will not undergo a downward adjustment [2] - New stocks from Xihua Technology and Tianmo Measurement are available for subscription [2] - The listing of Ruike Convertible Bond has been confirmed [2] Group 3 - Various convertible bonds are listed with their current prices, redemption prices, last trading days, last conversion days, conversion values, remaining scales, and the proportion of convertible bonds to the underlying stocks [5][7]

格隆汇12月11日丨万孚生物(300482.SZ)公布，近日，公司收到深圳市优美利投资管理有限公司（简 称"优美利投资"）的告知函，截至2025年12月11日收盘，优美利投资管理的证券投资基金合计持有"万 孚转债"1,230,467张，占公司可转债发行总量的20.51%。 ...

格隆汇12月11日丨万孚生物(300482.SZ)公布，近日，公司收到深圳市优美利投资管理有限公司（简 称"优美利投资"）的告知函，截至2025年12月11日收盘，优美利投资管理的证券投资基金合计持有"万 孚转债"1,230,467张，占公司可转债发行总量的20.51%。 ...

（文章来源：证券日报） 证券日报网讯 12月8日晚间，万孚生物发布公告称，公司董事会同意将不向下修正"万孚转债"转股价格 的期限由"2025年10月22日至2026年1月21日"调整为"2025年10月22日至2025年12月8日"。下一触发转股 价格修正条件的期间预计从2025年12月9日重新起算，若再次触发"万孚转债"转股价格向下修正条款， 届时公司将按照相关规定履行审议程序，决定是否行使"万孚转债"转股价格的向下修正权利。 ...

来源：上海证券报·中国证券网 上证报中国证券网讯 12月9日，中证转债指数午盘下跌0.36%，报482.17点。上涨方面，福蓉转债、沪 工转债、万孚转债、微导转债涨幅居前，分别涨8.33%、7.29%、4.31%、4.22%。下跌方面，瑞达转 债、豫光转债、中能转债跌幅居前，分别跌9.61%、4.63%、3.83%。 来源：上海证券报·中国证券网 | 代码 | 简称 | | 涨跌幅% ↓ | | --- | --- | --- | --- | | 113672.SH | 福营转债 | 179.692 | 8.33 | | 113593.SH | 沪工转债 | 150.978 | 7.29 | | 123064.SZ | 万孚转债 | 124.01 | 4.31 | | 118058.SH | 微导转债 | 320.031 | 4.22 | | 123251.SZ | 华医转信 | 161.062 | 3.78 | | 代码 | 简称 | | 涨跌幅% ↑ | | 128116.SZ | 瑞达转债 | 148.234 | -9.61 | | 110096.SH | 豫光转债 | 182.6 | -4.63 | ...

宏图转债：不下修 明天是鹰19转债的最后交易日了 这个债也是，顶着10%几的溢价，都转股了 | | 最低价:64.041 (2024-06-21) | | | | 最高价:128.440 (2021-09-13) | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 序号 | 目期 | 收盘价 | 成交额 | 转股价值 | 到期稅前 | 转股 | 剩余规模 | 换手率 | 11 股份 | | | | | (万元) | | 收益率 | 溢价率 | (亿元) | | | | 1 | 2025-12-08 | 112.622 | 8317.02 | | 97.16 -130.93% | 15.92% | 0.785 | 93.12% | 1.7 | | 2 | 2025-12-05 | 114.570 | 5824.89 | | 97.73 -162.29% | 17.23% | 1.218 | 41.75% | 1.7 | | 3 | 2025-12-04 | 114.834 | 6467.18 | | 97.16 -1 ...

Group 1 - The board of directors of Lanfang proposed to adjust the conversion price of Lanfang Convertible Bonds [1][2] - Wanfu Convertible Bonds will not undergo any adjustment [1][2] - Shareholders of Lihua Micro intend to reduce their holdings by no more than 3% of the company's shares [1] Group 2 - The current price of Jingxing Convertible Bonds is 177.100, with a strong redemption price of 100.290 and a remaining scale of 0.040 billion [4] - Montai Convertible Bonds have a current price of 122.900, a strong redemption price of 101.190, and a remaining scale of 0.800 billion [4] - New 23 Convertible Bonds are priced at 139.625, with a strong redemption price of 100.219 and a remaining scale of 2.259 billion [4] Group 3 - The current price of Pudong Development Bank Convertible Bonds is 110.850, with a redemption price of 110.000 and a remaining scale of 30.947 billion [6] - Tianlu Convertible Bonds are priced at 293.269, with a redemption price of 110.000 and a remaining scale of 0.602 billion [6] - Tongguang Convertible Bonds have a current price of 158.888, with a redemption price of 113.000 and a remaining scale of 0.757 billion [6]

Core Points - Wanfu Bio (300482) announced on October 21 that it will not lower the conversion price of its convertible bonds during the upcoming three-month period [1] - The board of directors decided that if the conversion price adjustment clause is triggered again after January 22, 2026, a new meeting will be held to determine whether to exercise the downward adjustment right [1] Summary by Sections - **Company Announcement** - Wanfu Bio will hold its fifth board meeting on October 21, 2025, to discuss the non-adjustment of the convertible bond conversion price [1] - The company will not propose a downward adjustment for the "Wanfu Convertible Bonds" during the specified three-month period from October 22, 2025, to January 21, 2026 [1] - **Future Considerations** - If the conversion price adjustment clause is triggered again after January 22, 2026, the board will reconvene to decide on the adjustment [1]

Core Viewpoint - The company announced that its stock price has been below 80% of the current conversion price for 10 trading days, which may trigger a downward adjustment of the conversion price for its convertible bonds [1] Group 1 - The stock price of Guangzhou Wanfu Biological Technology Co., Ltd. has been below the conversion price of 21.60 yuan per share since September 19, 2025 [1] - The company will hold a board meeting to decide whether to adjust the conversion price if the conditions for adjustment are triggered [1] - The company commits to timely information disclosure following the board's decision [1]

Key Points - The company, Wondfo Biotech, will distribute interest for its convertible bonds, with a payment of 18.00 RMB (including tax) for every 10 bonds held [1][2] - The interest payment period is from September 1, 2024, to August 30, 2025, with a coupon rate of 1.80% [2] - Holders of the convertible bonds must apply for conversion into company stock by August 29, 2025, to forgo interest payments for the current and subsequent periods [1][4] - The company has a long-term credit rating of AA, and the convertible bonds also hold an AA rating with a stable outlook [2] - The interest income tax for individual bondholders is set at a rate of 20%, which will be withheld by the payment agents [4][6] - Foreign institutional investors are exempt from corporate income tax and value-added tax on interest income from these bonds until December 31, 2025 [5]